About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

By: via Business Wire

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration’s (FDA) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products.

The FDA’s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise’s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSai™.

“This policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,” said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. “IPA has long championed the transition toward more ethical, efficient, and accurate methodologies. Our AI-powered LENSai™ platform and suite of integrated discovery tools were designed precisely to support this new era of translational science.”

IPA provides validated AI-driven methodologies that directly align with the FDA's shift towards New Approach Methodologies (NAMs). These advanced tools effectively address critical drug development challenges, including safety, toxicity, immunogenicity, and efficacy, by leveraging sophisticated predictive capabilities:

  1. Safety and Toxicity Prediction: IPA’s LENSai platform utilizes AI analytics to accurately predict potential toxicities by mapping drug interactions across the human proteome, significantly reducing the reliance on animal models.
  2. Immunogenicity Screening: The platform identifies immunogenic hotspots and predicts potential adverse immune responses, reducing the risk of anti-drug antibody formation and optimizing patient-specific strategies.
  3. Knowledge Graphs for Drug Efficacy: IPA’s semantic knowledge graphs integrate biological data and scientific literature, enabling precise predictions of drug efficacy and interactions in human systems.

Through transitioning from animal testing to AI-driven methodologies, IPA aims to streamline preclinical workflows, reduce development costs, uphold higher ethical standards, and support regulatory compliance in line with the FDA’s NAMs framework.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. These statements relate to, among other things, the anticipated benefits of IPA’s AI-driven methodologies, the integration of LENSai and BioStrand’s platforms into drug discovery, and the potential impact of regulatory shifts on IPA’s business and product development.

Although the Company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors largely beyond the Company’s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information on risks and uncertainties can be found in the Company’s Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should any of these risks materialize, actual results could vary significantly.

Readers are cautioned not to place undue reliance on forward-looking statements, which reflect the Company’s expectations only as of the date of this release. The Company assumes no obligation to update or revise these statements, except as required by law.

The FDA’s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise’s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies.

Contacts

More News

View More
Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers
Via MarketBeat
Topics Economy World Trade
Tickers AAP
3 Small Caps That Insiders Are Buying
Via MarketBeat
Topics Artificial Intelligence Retirement
Tickers AAOI NTWK THRY
3 Big Short Interest Names with Bullish Setups
Via MarketBeat
Topics Artificial Intelligence
Tickers ASX:PDN DLO HIMS TEM
Why Datavault May be the Penny AI Stock Investors Have Waited For
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM
These 3 Stocks Boosting Buybacks Have Rallying Potential
Via MarketBeat
Tickers CMG TKO WDAY
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.